Comparative Outcomes of Meropenem–Vaborbactam vs. Ceftazidime–Avibactam Among Adults Hospitalized with an Infectious Syndrome in the US, 2019–2021

<b>Background/Objectives</b>: Meropenem–vaborbactam (MEV) and ceftazidime–avibactam (CZA) are active against “urgent threat” pathogens like carbapenem-resistant Enterobacterales (CRE). However, few studies have compared outcomes between them. <b>Methods</b>: To explore comparative outcomes of MEV vs...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Marya D. Zilberberg, Brian H. Nathanson, Mark A. Redell, Kate Sulham, Andrew F. Shorr
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	MDPI AG 2025-01-01
Цуврал:	Antibiotics
Нөхцлүүд:	comparative outcomes multidrug resistance hospitalization outcomes epidemiology
Онлайн хандалт:	https://www.mdpi.com/2079-6382/14/1/29
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!